In this Issue:
Ceritinib in ALK-rearranged NSCLC
Restoring muscle mass and strength after radical therapy
Cost effectiveness of EML4-ALK fusion testing and crizotinib
Prognostic impact of minimal pleural effusion
Shifting patterns in interpretation of NSCLC trial outcomes
Dacomitinib in advanced NSCLC
Risk model predicts disease recurrence
Inflammation-based prognostic indices
Amrubicin + cisplatin in extensive-disease SCLC
Amrubicin in refractory SCLC
Please login below to download this issue (PDF)